519353 — Novyra Pharmachem Share Price
Last trade - 00:00- IN₹53.81m
- IN₹52.03m
- IN₹1.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.65 | ||
| Price to Tang. Book | 8.65 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -871.24% | ||
| Return on Equity | -163.51% | ||
| Operating Margin | -296.04% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | n/a | 1.5 | n/a | n/a | 1.04 | n/a | n/a | -11.38% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Novyra Pharmachem Limited, formerly Bansisons Tea Industries Limited, is an India-based company. The Company is engaged in business activities relating to pharmaceuticals, chemicals and allied trading/business operations. Its segments include Pharma, Real Estate, and Tea Estate.
Directors
- Last Annual
- March 31st, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- September 8th, 1987
- Public Since
- July 10th, 2017
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- Bombay Stock Exchange
- Shares in Issue
- 6,330,000
- Address
- 264, MG Road, Darjeeling, SILIGURI, 734405
- Web
- https://www.novyrapharmachemltd.com
- Phone
- +91 3532501808
- Auditors
- M/S DGMS and Company
Latest News for 519353
Upcoming Events for 519353
Similar to 519353
Abram Food
Bombay Stock Exchange
Aelea Commodities
Bombay Stock Exchange
Ajanta Soya
Bombay Stock Exchange
Alna Trading and Exports
Bombay Stock Exchange
Ambar Protein Industries
Bombay Stock Exchange
FAQ
As of Today at 04:25 UTC, shares in Novyra Pharmachem are trading at IN₹8.50. This share price information is delayed by 15 minutes.
Shares in Novyra Pharmachem last closed at IN₹8.50 and the price had moved by +31.38% over the past 365 days. In terms of relative price strength the Novyra Pharmachem share price has outperformed the S&P BSE 100 Index by +42.6% over the past year.
There is no consensus recommendation for this security.
Find out moreNovyra Pharmachem does not currently pay a dividend.
Novyra Pharmachem does not currently pay a dividend.
Novyra Pharmachem does not currently pay a dividend.
To buy shares in Novyra Pharmachem you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹8.50, shares in Novyra Pharmachem had a market capitalisation of IN₹53.81m.
Here are the trading details for Novyra Pharmachem:
- Country of listing: India
- Exchange: BSE
- Ticker Symbol: 519353
Based on an overall assessment of its quality, value and momentum Novyra Pharmachem is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novyra Pharmachem. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -40.61%.
As of the last closing price of IN₹8.50, shares in Novyra Pharmachem were trading +1.41% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Novyra Pharmachem PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹8.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Novyra Pharmachem's directors